Substance Use and Risky Sexual Behavior in the PrEP Outpatient Clinic at the University Hospital of Brasília-Reference-Cited by-同舟云学术

Substance Use and Risky Sexual Behavior in the PrEP Outpatient Clinic at the University Hospital of Brasília

Published:2023-06-16 Issue:6 Volume:8 Page:323
ISSN:2414-6366
Container-title:Tropical Medicine and Infectious Disease
language:en
Short-container-title:TropicalMed

Author:

da Costa Alan Rodrigues¹,Barros Jônatas Ferreira¹,Lima Valéria Paes¹,Magalhães Camila¹,Silva Hellen Kássia Rezende¹,Deusdará Rodolfo¹^ORCID,de Souza Lapa Juliana¹

Affiliation:

1. Núcleo de Medicina Tropical, Faculdade de Medicina, Campus Universitário Darcy Ribeiro, Universidade de Brasília, Asa Norte, Brasília 70910-900, Brazil

Abstract

(1) Background: To evaluate the epidemiological profile of people who use drugs at the PrEP outpatient clinic of the University Hospital of Brasília; (2) Methods: Cross-sectional study with a review of data from medical records referring to the first medical consultation. The prevalence ratio was calculated using a Poisson regression model with robust variance; (3) Results: A total of 53% of subjects reported drug use in the last 3 months. The unadjusted prevalence ratio of drug use in trans women was PR: 9.0 (95%CI: 1.4–57.5). people who use drugs have a 1.9 times higher prevalence of STI diagnosis, and a 2.4 times higher prevalence of partners compared to non-users; (4) Conclusions: Substance use was associated with a higher STI prevalence ratio and number of sexual partners.

Publisher

MDPI AG

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Immunology and Microbiology

Link

https://www.mdpi.com/2414-6366/8/6/323/pdf

Reference35 articles.

1. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância (2018). Protocolo Clínico e Diretrizes Terapêuticas Para Profilaxia Pré-Exposição (PrEP) de Risco à Infecção Pelo HIV, Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância.

2. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomized trial;McCormack;Lancet,2016

3. Ministério da Saúde (2023). Coordenação-Geral de Vigilância do HIV/AIDS e das Hepatites Virais. Nota Técnica Nº 8/2023. Recomendações e Atualizações Acerca do Uso da Profilaxia Pré-Exposição de Risco à Infecção Pelo HIV (PrEP) Oral, Incluindo a Modalidade “sOB DEMANDA”, Ministério da Saúde.

4. Ministério da Saúde (2022). Protocolo Clínico e Diretrizes Terapêuticas para Profilaxia Pré-Exposição (PrEP) de Risco à Infecção pelo HIV [recurso eletrônico]/Ministério da Saúde, Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde, Secretaria de Vigilância em Saúde, Ministério da Saúde. [1st ed.].

5. Predictors of Human Immunodeficiency Virus Pre-Exposure Prophylaxis (PrEP) Uptake in a Sexual Health Clinic With Rapid PrEP Initiation;Wagner;Open Forum Infect. Dis.,2023